Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Non-Current Debt (2021)

Whitehawk Therapeutics (WHWK) has disclosed Non-Current Debt for 1 consecutive years, with $5.8 million as the latest value for Q4 2021.

  • On a quarterly basis, Non-Current Debt changed N/A to $5.8 million in Q4 2021 year-over-year; TTM through Dec 2021 was $5.8 million, a N/A change, with the full-year FY2021 number at $5.8 million, changed N/A from a year prior.
  • Non-Current Debt was $5.8 million for Q4 2021 at Whitehawk Therapeutics, roughly flat from $5.8 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $5.8 million in Q3 2021 to a low of $5.8 million in Q3 2021.